pharmaphorum

JANUARY 22, 2021

In this article, we focus in particular on how COVID-19 may be changing prescribing decisions using market research and claims data. Source: CRA market research (conducted June 2020). Source: CRA claims data analysis (using claims through June 2020). Changes in Prescribing by Specialty. Changes in Prescribing by Specialty.

Specialty Pharmacies 95

Specialty Pharmacies Pharmaceutical Companies Pharmaceutical Companies Vaccines 95

The People's Pharmacy

MAY 29, 2023

We also located an article in the Canadian Medical Association Journal (Dec. We first wrote about cimetidine for shingles in 2020. One article described the heartburn medicine Tagamet as having a positive impact. We did, however, find an interesting case series in The New England Journal of Medicine (Feb. Tagamet for Warts?

Immunization 72

Immunization Labelling Pharmaceutical Companies Pharmaceutical Companies 72

Pharma Marketing Network

SEPTEMBER 28, 2020

With a lack of knowledge and no known treatment, cure, or vaccine, an uncomfortable uncertainty took hold as quarantines were imposed: which people and what businesses would survive this biological blindside? The questions Pharma companies seek answers to now, and post-Covid -19, include: What will 2021 look like? What will we inspire?

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

Pharma Marketing Network

SEPTEMBER 28, 2020

With a lack of knowledge and no known treatment, cure, or vaccine, an uncomfortable uncertainty took hold as quarantines were imposed: which people and what businesses would survive this biological blindside? The questions Pharma companies seek answers to now, and post-Covid -19, include: What will 2021 look like? What will we inspire?

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

AUGUST 13, 2020

Of these three societal pillars, it is, perhaps surprisingly, business that has stepped up to the plate most assuredly in 2020 – led by some of the world’s strongest brands. Pfizer has four different mRNA platform vaccines in play against one-another: a radical new approach for them. Government and the media didn’t fare any better.

Health and Personal Care Stores 90

Health and Personal Care Stores Vaccines Communication Pharmaceutical Companies 90

pharmaphorum

OCTOBER 7, 2021

Use of these platforms was however already trending up before the crisis, and there’s every sign demand will stay high from now on, according to Sjors van den Camp, commercial director at Online Seminar – a company whose heritage in this sector goes back more than a decade. The crisis that changed everything.

Communication 95

Communication Labelling Pharmaceutical Companies Pharmaceutical Companies 95

pharmaphorum

JANUARY 5, 2021

One bright spot in an otherwise dreadful year: the pharmaceutical industry has discovered it can do things it never dreamed possible. Anyone who proposed that a novel, deadly virus would spread, with a vaccine developed demonstrating 95% efficacy, and approved for patients in less than a year would have been scoffed at.

Hospitals 105

Hospitals Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

pharmaphorum

DECEMBER 2, 2020

Similarly, in 2019 Pfizer announced a deal to merge its Upjohn generics business with Mylan, creating a combined company called Viatris. The $12 billion deal was cleared in November 2020, creating a generics behemoth with annual sales of around $19 to $20 billion and operations in 165 markets around the word.

Compounding 128

Compounding Vaccines Pharmaceutical Companies Pharmaceutical Companies 128

pharmaphorum

JANUARY 9, 2023

This article is the first part of three and covers the first three of nine predictions, here focusing on global healthcare environmental challenges and what they mean for the pharmaceutical industry. Some of the more resilient launches since 2020 have had these benefits to health systems. Pharma’s starting to wake up to this.

Vaccines 92

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 92

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. On average, launches of 2020’s cohorts both underperformed. The scope of the problem. Launches, therefore, were happening.

HIV Treatment and Prevention Agents 59

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 59

PharmaShots

MAY 1, 2023

Factors like digitalization, patent expiry, growing competition, and others put direct or indirect impacts on the revenue of the companies Ever wondered, why for the past few days our feed has been brimming with layoffs news? The pharmaceutical industry is an ever-growing sector driven by innovation and astounding technology.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Vaccines 40

PharmaShots

MAY 1, 2023

Factors like digitalization, patent expiry, growing competition, and others put direct or indirect impacts on the revenue of the companies Ever wondered, why for the past few days our feed has been brimming with layoffs news? The pharmaceutical industry is an ever-growing sector driven by innovation and astounding technology.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Vaccines 40

pharmaphorum

JANUARY 6, 2022

IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Dealmaking in RNA Therapeutics rose 13-fold from 2019 to 2020.

Vaccines 105

Vaccines Pharmaceutical Companies Pharmaceutical Companies 105